Stocks and Investing
Stocks and Investing
Thu, January 2, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, December 31, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, December 30, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Charles Duncan Reiterated (AXSM) at Buy with Increased Target to $125 on, Dec 30th, 2019
Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy with Increased Target from $104 to $125 on, Dec 30th, 2019.
Charles has made no other calls on AXSM in the last 4 months.
There is 1 other peer that has a rating on AXSM. Out of the 1 peers that are also analyzing AXSM, 0 agree with Charles's Rating of Hold.
This is the rating of the analyst that currently disagrees with Charles
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $158 on, Monday, December 16th, 2019